Skip to content

Establishing Daily Applicable Parameters for Using Magnetic Resonance Spectroscopy of Spinal Cord

Establishing Daily Applicable Parameters for Using Magnetic Resonance Spectroscopy of Spinal Cord

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06548776
Enrollment
10
Registered
2024-08-12
Start date
2024-09-04
Completion date
2026-08-25
Last updated
2026-08-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Spinal Cord

Brief summary

To learn if MRS can effectively assess spinal cord lesions.

Detailed description

Primary Objective: Establish the feasibility and spectrum of MRS for adult patients while mapping the total spine spectrum at short TEs to allow for future comparison with patients to assess spinal cord lesions malignant potential and grade. Secondary Objective: Test success of the spectrum by implementing the protocol on 3 low volume LMD receiving LMD receiving CSI. This will allow us to test reproducibility of the protocol and test effect of radiation on spinal cord at different time frames. This will serve as secondary data for subsequent trials targeting functional statues after radiation and tumor grading predictability of MRS.

Interventions

DIAGNOSTIC_TESTMagnetic Resonance Spectroscopy (MRS) Scan

Participants will receive MRS Scan

Sponsors

M.D. Anderson Cancer Center
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

Volunteers: * Adults \> 18 years * Healthy with no malignancy, demyelinating disease, back pain, degenerative disease, or spinal cord lesions. * Consent able patients. Patients with low volume LMD to receive treatment CNS radiation: * Adults \> 18 years old. * MR or CSF with evidence of LMD. * Patients to receive CSI as part of standard treatment of LMD disease. * Consent able patients, willingness and ability to comply with the study procedures. * No spinal cord lesions only LMD disease * Recruitment by radiation oncology faculty in consultation with Dr. De. . .

Exclusion criteria

Volunteers: * Age \< 18 years * Pregnant or breastfeeding individuals. * History of cancer. * History of spinal cord lesions including malignant, demyelinating, or inflammatory. * History of prior spinal surgery. * History of implantable devices. * History of MR claustrophobia. * Degenerative disease or spinal/back pain including myelopathy and radiculopathy. * Scoliosis. Patients with LMD: * Age \< 18 years * History of spinal cord lesions including malignant, demyelinating, or inflammatory. * History of prior spinal surgery. * History of implantable devices. * History of MR claustrophobia. * Degenerative disease or spinal/back pain including myelopathy and radiculopathy. * Scoliosis.

Design outcomes

Primary

MeasureTime frameDescription
Safety and Adverse Events (AEs)Through study completion; an average of 1 year.Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE)

Countries

United States

Contacts

PRINCIPAL_INVESTIGATORRami Eldaya, MD

M.D. Anderson Cancer Center

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Sep 1, 2026